Penumbra Inc. (PEN)
Here's Why You Should Retain Penumbra Stock in Your Portfolio Now
Investors feel optimistic about PEN's strong growth prospects in the Thrombectomy business. Yet, unfavorable forex impacts are concerning.
Why Penumbra Stock Zoomed Nearly 5% Higher Today
A researcher initiated coverage of the medical device maker with a confident buy recommendation. He sees multiple positive factors that should propel its growth.
PEN Stock to Gain From CE Mark Approval for its CAVT Technologies
Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.
Why Is Penumbra (PEN) Up 20% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Penumbra: Growth In Its Thrombectomy Portfolio Should Lead To Strong Earnings
Penumbra is continuing to take share with its new CAVT devices against its closest competition in the VTE space. PEN reduced guidance after Q2 earnings, but the market took it in stride, with difficult comparisons against 2023. PEN has recently announced a supportive $200m buyback, which will put a floor under the shares here.
Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Penumbra (PEN) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Penumbra, Inc. (PEN) Q2 2024 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Michael Sarcone - Jefferies Pito Chickering - Deutsche Bank Richard Newitter - Truist Securities Operator Good afternoon. My name is Aaron, and I will be your conference operator for today.
Penumbra (PEN) Q2 Earnings and Revenues Beat Estimates
Penumbra (PEN) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.43 per share a year ago.
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Penumbra (PEN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
